Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to... see more

GREY:TBPMQ - Post Discussion

View:
Post by NSX001 on Jul 12, 2022 1:16pm

TBP.WT.A

It appears that it may only apply to the TBP.WT.A warrants, they're trading at 0.005 cents, hence the delisting.

The regular shares are still trading as I type this.

So, sorry, I may have jumped a little to quick on this.

NSX001
Comment by Normandt on Jul 12, 2022 4:00pm
Warrant are expired, that's all. //// Warrant exercise price: 40 cents per share at any time prior to 5 p.m. Toronto time on the date that is 36 months following the closing date of the offering (The expiry date of the warrants is July 12, 2022, in the warrant indenture.)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities